Drugs / TJAOA103
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07160127 | Sep 2025 → Jun 2027 expected | urethral syndrome | Tongji Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TJAOA103 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07160127 ↗ |
| Known as | Tongji Anti-Ovarian Aging 103 | “we have invented a novel TCM formula, Tongji Anti-Ovarian Aging 103 (TJAOA103).” NCT07160127 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “Chinese herbal formula TJAOA103” NCT07160127 ↗ |
| Route | Oral | “TJAOA103 should be taken orally twice a day” NCT07160127 ↗ |